A new genre of diagnostic tests for the era of personalized medicine
A new genre of medical tests – which determine whether a medicine is right for a patient’s genes – are paving the way for increased use of personalized medicine, according to the cover story in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world’s largest scientific society.
Celia Henry Arnaud, C&EN senior editor, points out that the U.S. Food and Drug Administration has approved several precedent-setting cancer drugs that provide a glimpse of the “personalized” medical care that awaits patients with cancer and other diseases in the future. Personalized medicine involves selecting treatments that work best with the set of genes present in each individual person. Such treatments work only for patients with conditions related to mutations, or alterations, in certain genes.
The article describes new “companion diagnostics,” or diagnostic tests that already have gone into use, with more on the horizon, to identify patients most likely to benefit from a medication. Doctors must perform these tests before starting treatment. Arnaud describes how pharmaceutical companies are embracing an approach that involves co-development of drugs and companion diagnostics that can be used in clinical trials and later when a medication goes into general use.
American Chemical Society, ACS is a congressionally chartered independent membership organization which represents professionals at all degree levels and in all fields of chemistry and sciences that involve chemistry.
Learn more about ACS.